16:39 IST
NSE
Regulatory Approval
Natco Pharma Regulatory Approval
Natco Pharma received tentative U.S. FDA approval for Olaparib tablets. The reference drug Lynparza reported USD 1.4 billion in U.S. sales.
Natco Pharma Ltd
- Share price
- ₹810.70
- Market cap
- ₹15,903 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.9×Sector 47.4×
- Promoter holding
- 49.42%+0.00% QoQ
- FII holding
- 16.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 6Board Meeting Date 4Financial Results 3Capital Structure Change 3Board Meeting Outcome 3Regulatory Approval 2Other Announcement 2Legal & Regulatory 2Fund Raise 2Acquisition 2Promoter Selling (Off-Market) 1Merger & Restructuring 1Management Change 1Dividend 1Business Update 1Annual Report 1Annual General Meeting 1
Time
2 announcements with these filters
11:14 IST
BSE
Regulatory Approval
Natco Pharma Regulatory Approval
Natco Pharma and Lupin received U.S. FDA approval for Eribulin Mesylate Injection. The product targets a USD 43.7 million market for metastatic breast cancer treatment.
- Value
- ₹415.1 Cr